Literature DB >> 7706807

Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.

E Hogervorst1, S Jurriaans, F de Wolf, A van Wijk, A Wiersma, M Valk, M Roos, B van Gemen, R Coutinho, F Miedema.   

Abstract

To gain insight into determinants that define the duration of the asymptomatic period preceding AIDS, groups of long-term asymptomatic (LTA) person (> 7 years of follow-up) and slow and rapid progressors of human immunodeficiency virus infection were studied. LTAs had no clinical manifestations of AIDS or immunologic abnormalities in 7 years of follow-up. RNA copy numbers, gag- and env-specific, and neutralizing antibody titers in serum were determined 1 and 5 years after seroconversion or entry into the cohort. Early in infection, before immunologic markers or clinical manifestations allowed group discrimination, subjects who were later classified as LTAs had significantly less serum viral RNA than progressors. No significant increase in virus load was found in progressors, indicating that the initial load defines clinical outcome. In slow progressors, high virus load was associated with high p24-specific antibody titers, suggesting that delay of clinical manifestations of AIDS may be related to the presence of high levels of p24-specific but not V3-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706807     DOI: 10.1093/infdis/171.4.811

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Comparison of levels of human immunodeficiency virus type 1 RNA in plasma as measured by the NucliSens nucleic acid sequence-based amplification and Quantiplex branched-DNA assays.

Authors:  C C Ginocchio; S Tetali; D Washburn; F Zhang; M H Kaplan
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

Review 2.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

3.  Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.

Authors:  E L Delwart; H Pan; H W Sheppard; D Wolpert; A U Neumann; B Korber; J I Mullins
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

Review 5.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 6.  Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

Authors:  G J Moyle; B G Gazzard; D A Cooper; J Gatell
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

7.  The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain.

Authors:  M Schreiber; C Wachsmuth; H Müller; S Odemuyiwa; H Schmitz; S Meyer; B Meyer; J Schneider-Mergener
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.

Authors:  Koen K A Van Rompay; Kristina Abel; Patricia Earl; Pamela A Kozlowski; Juliet Easlick; Joseph Moore; Linda Buonocore-Buzzelli; Kimberli A Schmidt; Robert L Wilson; Ian Simon; Bernard Moss; Nina Rose; John Rose; Marta L Marthas
Journal:  Vaccine       Date:  2009-12-06       Impact factor: 3.641

9.  Serum HIV-1 RNA load to predict CD4+ T-cell depletion in asymptomatic patients.

Authors:  A Lafeuillade; C Poggi; P Pellegrino; N Profizi
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

10.  Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

Authors:  Nancy L Haigwood; David C Montefiori; William F Sutton; Janela McClure; Andrew J Watson; Gerald Voss; Vanessa M Hirsch; Barbra A Richardson; Norman L Letvin; Shiu-Lok Hu; Philip R Johnson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.